Detalhe da pesquisa
1.
Clustering of known low and moderate risk alleles rather than a novel recessive high-risk gene in non-BRCA1/2 sib trios affected with breast cancer.
Int J Cancer
; 147(10): 2708-2716, 2020 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32383162
2.
Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial.
Br J Cancer
; 122(10): 1453-1460, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32203207
3.
Addition of a 161-SNP polygenic risk score to family history-based risk prediction: impact on clinical management in non-BRCA1/2 breast cancer families.
J Med Genet
; 56(9): 581-589, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31186341
4.
Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy.
Int J Mol Sci
; 21(4)2020 Feb 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-32085669
5.
Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials.
Cancer
; 125(2): 307-316, 2019 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30335191
6.
Functional Analysis of Missense Variants in the Putative Breast Cancer Susceptibility Gene XRCC2.
Hum Mutat
; 37(9): 914-25, 2016 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27233470
7.
Rare variants in XRCC2 as breast cancer susceptibility alleles.
J Med Genet
; 49(10): 618-20, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-23054243
8.
High-dose alkylating chemotherapy in BRCA-altered triple-negative breast cancer: the randomized phase III NeoTN trial.
NPJ Breast Cancer
; 9(1): 75, 2023 Sep 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37689749
9.
Ten-year follow-up of the observational RASTER study, prospective evaluation of the 70-gene signature in ER-positive, HER2-negative, node-negative, early breast cancer.
Eur J Cancer
; 175: 169-179, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36126477
10.
Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant.
Eur J Cancer
; 164: 39-51, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35172272
11.
Road Map to Safe and Well-Designed De-escalation Trials of Systemic Adjuvant Therapy for Solid Tumors.
J Clin Oncol
; 38(34): 4120-4129, 2020 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33052755
12.
Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial.
ESMO Open
; 5(6): e000979, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33154022
13.
Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial.
J Clin Oncol
; 38(11): 1186-1197, 2020 04 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32083990
14.
Exome sequencing of germline DNA from non-BRCA1/2 familial breast cancer cases selected on the basis of aCGH tumor profiling.
PLoS One
; 8(1): e55734, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23383274
15.
Whole exome sequencing suggests much of non-BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles.
PLoS One
; 8(2): e55681, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23409019
16.
Genetic variants in TGFß-1 and PAI-1 as possible risk factors for cardiovascular disease after radiotherapy for breast cancer.
Radiother Oncol
; 102(1): 115-21, 2012 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-22100658